PHILADELPHIA, May 23 /PRNewswire/ -- Late-breaking advances in engineered antibodies research in post-genomic high-throughput antibody R&D, novel targets/selection, MAb generation, and pre-clinical and clinical advances will be the focus of the ``Engineered Antibodies Accelerating Drug Discovery and Development Conference & Exposition'' taking place in Philadelphia, PA on September 18-19, 2001, announces Strategic Research Institute.
New presentations on program are Millennium's Rapid Antibody Development Systems and Abgenix's XenoMax(TM) Technology, a highly efficient system for generating fully human antibodies. Also featured on program is Altarex's broad technology platform, which evaluates MAbs for their potential to alter antigen processing in treating cancer.
The meeting, divided into four discrete sections, of 5-8 papers each: 1) Post Genomic HTP Antibody R & D, 2) Novel targets & Selection, 3) MAb Generation, and 4) Preclinical/Clinical Progress, will feature prominent pharmaceutical, biotechnology, and academic researchers in the developing and commercializing of this important new therapeutic technology. The final section will also discuss the clinical trials of certain antigen-based therapeutics.
Also presenting papers on behalf of the industry will be: Eli Lilly, GlaxoSmithKline, Genentech, Amgen, Wyeth Ayerst, Millennium Pharmaceuticals, IDEC Pharmaceuticals, The Dow Chemical Company, ICOS Corporation, Imclone Systems, Celltech Group, Biosite, Abgenix, Medarex, Crucell, Altarex, EPIcyte, Xenerex-Division of Avanir Pharma, Biovation and Xencor, while Harvard Medical School and Beckman Research Institute-City of Hope will represent the academic community. The scope of this conference will be addressed by Centocor. Other highlights of the program include: Antibody-based Growth Factor Receptor Inhibitors for Cancer Therapy: Experiences with IMC-C225 (anti-EGFR antibody) and IMC-1C11 (anti-KDR antibody) by IMCLONE SYSTEMS Antibodies for Immune Modulation; Rapid Development and Clinical Applications by MEDAREX Human Therapeutic Antibodies: Opportunities and Challenges on the Road Ahead by ELI LILLY.
To receive the full agenda and/or register for the conference, please contact Ed Drilon at edrilon@srinstitute.com or at 212.967.0095, x233. Include your fax number, affiliation and mailing address. |
